E-LIB Suche - Ergebnisse für: Bykov, Katsiaryna

1

Risk of fall or fracture with concomitant use of prescripti..:

Khan, Nazleen F. ; Bykov, Katsiaryna ; Katz, Jeffrey N....
Pharmacoepidemiology and Drug Safety. 33 (2024) 3 - p. , 2024

Link: https://doi.org/10.1002/..

2

Trends in Use and Evidence of Adherence to Risk Evaluation ..:

Mahesri, Mufaddal ; Sarpatwari, Ameet ; Huybrechts, Krista F....
Drug Safety. , 2024

Link: https://doi.org/10.1007/..

3

Concomitant Use of Sodium‐Glucose Cotransporter 2 Inhibitor..:

Bea, Sungho ; Lee, Hyesung ; Park, Sohee...
Clinical Pharmacology & Therapeutics. 115 (2024) 5 - p. 1132-1140 , 2024

Link: https://doi.org/10.1002/..

4

Association between initiation of fluoroquinolones and hosp..:

Wang, Junyi ; Gagne, Joshua J ; Kattinakere-Sreedhara, Sushama..
BMJ. , 2022

Link: https://doi.org/10.1136/..

5

Breaking Research Silos and Stimulating "Innovation at the ..:

Shmuel, Shahar ; Leonard, Charles E ; Bykov, Katsiaryna...
American Journal of Epidemiology. 192 (2022) 3 - p. 323-327 , 2022

Link: https://doi.org/10.1093/..

6

Comparative Risk of Opioid Overdose With Concomitant Use of..:

Khan, Nazleen F. ; Bykov, Katsiaryna ; Barnett, Michael L....
Neurology. 99 (2022) 13 - p. , 2022

Link: https://doi.org/10.1212/..

7

Coprescription of Opioids With Other Medications and Risk o..:

Khan, Nazleen F. ; Bykov, Katsiaryna ; Glynn, Robert J...
Clinical Pharmacology & Therapeutics. 110 (2021) 4 - p. 1011-1017 , 2021

Link: https://doi.org/10.1002/..

8

Prevalence of Avoidable and Bias‐Inflicting Methodological ..:

Bykov, Katsiaryna ; Patorno, Elisabetta ; D'Andrea, Elvira...
Clinical Pharmacology & Therapeutics. 111 (2021) 1 - p. 209-217 , 2021

Link: https://doi.org/10.1002/..

9

Postoperative inpatient utilization of opioid and opioid‐sp..:

Bykov, Katsiaryna ; Patorno, Elisabetta ; Franklin, Jessica M...
Pharmacoepidemiology and Drug Safety. 30 (2021) 3 - p. 390-394 , 2021

Link: https://doi.org/10.1002/..

10

A Multi-modal Approach to Evaluate the Impact of Risk Evalu..:

Sarpatwari, Ameet ; Mitra-Majumdar, Mayookha ; Bykov, Katsiaryna...
Drug Safety. 44 (2021) 7 - p. 743-751 , 2021

Link: https://doi.org/10.1007/..

11

Bias in case‐crossover studies of medications due to persis..:

Bykov, Katsiaryna ; Wang, Shirley V. ; Hallas, Jesper...
Pharmacoepidemiology and Drug Safety. 29 (2020) 9 - p. 1079-1085 , 2020

Link: https://doi.org/10.1002/..

12

Drug‐Drug Interaction Surveillance Study: Comparing Self‐Co..:

Bykov, Katsiaryna ; Li, Hu ; Kim, Sangmi...
Clinical Pharmacology & Therapeutics. 109 (2020) 5 - p. 1353-1360 , 2020

Link: https://doi.org/10.1002/..

13

Glucose‐lowering medications and the risk of cancer: A meth..:

Bykov, Katsiaryna ; He, Mengdong ; Franklin, Jessica M....
Diabetes, Obesity and Metabolism. 21 (2019) 9 - p. 2029-2038 , 2019

Link: https://doi.org/10.1111/..

14

A Case‐Crossover–Based Screening Approach to Identifying Cl..:

Bykov, Katsiaryna ; Schneeweiss, Sebastian ; Glynn, Robert J...
Clinical Pharmacology & Therapeutics. 106 (2019) 1 - p. 238-244 , 2019

Link: https://doi.org/10.1002/..

15

Response to "The Self‐Controlled Case Series Design as a Vi..:

Bykov, Katsiaryna ; Gagne, Joshua J.
Clinical Pharmacology & Therapeutics. 107 (2019) 2 - p. 323-323 , 2019

Link: https://doi.org/10.1002/..